Showing 1 - 10 of 66
Persistent link: https://www.econbiz.de/10011241533
Persistent link: https://www.econbiz.de/10011151220
Our review confirmed that the BIA is not yet a well-established technique in the literature and many published studies still fail to reach an acceptable quality. In particular, BIAs funded by pharmaceutical companies appear to be tailored to show short-term savings induced by new, highly priced...
Persistent link: https://www.econbiz.de/10011000857
The European studies we analysed are mostly based on weak sources of data. Because of the limited information on vaccine effectiveness and lack of epidemiological and economic data, the need for extensive recourse to assumptions leads to great within- and between-study variability generated by...
Persistent link: https://www.econbiz.de/10011001463
Persistent link: https://www.econbiz.de/10010634521
Persistent link: https://www.econbiz.de/10010539841
Persistent link: https://www.econbiz.de/10010169392
Persistent link: https://www.econbiz.de/10004185471
Objective We examined Continuing Medical Education (CME) systems in a sample of six EU countries: Austria, Belgium, France, Italy, Norway, and the UK. The aim of this comparative study was to assess the main country-specific institutional settings applied by governments.Methods A common scheme...
Persistent link: https://www.econbiz.de/10008620243
Objective To contribute to the debate whether extending public coverage of influenza vaccination to healthy workers is cost-effective, particularly in the perspective of EU countries.Methods First, we reviewed the recent international literature on the extension of vaccination to subjects aged...
Persistent link: https://www.econbiz.de/10009249941